International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-5 doi: 10.5281/zenodo.13706984
Original Research Article
FORT: Predicting IVF/ICSI Outcomes
Published
Sept. 6, 2024
Abstract

Background:The study focused on evaluating the Follicular Output Rate (FORT) as a prognostic indicator for how well a patient responds to Follicle-Stimulating Hormone (FSH) during ovarian stimulation in IVF/ICSI cycles and its association with reproductive outcomes. The study involved calculating the FORT for a cohort of 138 women undergoing IVF/ICSI. FORT was determined by comparing the number of preovulatory follicles at the time of hCG administration to the initial antral follicle count (AFC) before stimulation. The accuracy of FORT as a prognostic indicator was evaluated by comparing it with actual reproductive outcomes, such as the number of mature oocytes retrieved, quality of oocytes, number of embryos, chemical and clinical pregnancy rates. Result: The mean age (±SD) of the women was 31.36 years (± 3.28 years), the mean FORT was 53.453. Based on FORT values, study population was divided into three groups, those with low (≤42), medium (>42 to 58) or high FORT (>58). Those with Positive pregnancies had much higher FORT levels (74.025) than those with Negative pregnancies (38.975) and this result was statistically significant. FORT and number of mature oocytes (MII) retrieved were positively correlated and the number of oocytes and embryos obtained increased progressively from the low to the high FORT groups. Conclusion: The study found that FORT is a reliable and accurate indicator of ovarian response to FSH. A higher FORT correlates with a better response to FSH, leading to more mature follicles and higher quality oocytes.

Recommended Articles
Loading Image...
Volume-5, Issue-5
Citations
552 Views
495 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved